Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a diabetes drug shield hearts from chemo damage?

NCT ID NCT06888505

Disease control Sponsor: Hawler Medical University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether dapagliflozin (Farxiga), a drug used for diabetes and heart failure, can prevent heart damage caused by anthracycline chemotherapy. 94 adults with cancer took either dapagliflozin or a placebo daily for four months alongside their chemo. Researchers measured heart function and blood markers to see if the drug offered protection.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
dapagliflozin (Farxiga)
What this could lead to
If it works, this could point toward a way to protect the heart during chemotherapy, reducing the risk of long-term heart damage.
What could go wrong
This is a small, early-phase trial with only 94 participants. The results may not apply to everyone, and the drug may not provide meaningful protection in larger studies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

94 people

The number who actually took part.

Started

Sep 2024

Finished

Sep 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 70 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Histologically confirmed breast cancer (or other cancers as relevant to the study). * Age 18-70 years. * Planned treatment with anthracycline-based chemotherapy * Normal kidney function, defined as serum creatinine 0.6-1.2 mg/dL. * Normal liver function, defined as ALT and AST 10-40 U/L. * Eastern Cooperative Oncology Group (ECOG) performance status of 0-2. * Willingness to participate and provide written informed consent. Exclusion Criteria: * History of symptomatic heart failure (NYHA class III-IV) or prior anthracycline-related cardiac dysfunction. * Previous use of Dapagliflozin. * Pregnancy or breastfeeding. * Severe renal impairment (eGFR \< 30 mL/min/1.73m²). * Uncontrolled diabetes mellitus (HbA1c \> 9%). * Active or recurrent urinary tract infections (UTIs) within the last 6 months. * Known hypersensitivity to Dapagliflozin or related compounds. * Concurrent participation in another clinical trial investigating cardioprotective agents.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Anthracyclines-induced cardiotoxicity are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

breast cancer cardiomyopathy due to anthracyclines Cardiotoxicity

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Anthracyclines-induced cardiotoxicity Cardiotoxicity

Contacts and locations

Locations

  • Azadi Oncology Centre

    Duhok, Duhok Governorate, 42001, Iraq

More trials for these conditions

Other studies related to the condition(s) this trial covers.